Jon C. Mirsalis
Jon C. Mirsalis, Ph.D., DABT, has more than 30 years of experience in the management and conduct of preclinical development projects for the translation of pharmaceutical products, vaccines, and medical devices into human clinical trials. A large portion of his career has focused on accelerating development of therapies for infectious diseases and biothreat agents, including fast-tracking therapies for influenza, MERS, plague, and anthrax. Mirsalis has directly supervised the development of more than 200 interventional agents for infectious disease.
Mirsalis joined SRI in 1981 as a staff scientist, and subsequently served as a program director, department director, laboratory director, associate director, and managing director. He also currently serves as director of SRI's Toxicology and Pharmacology Laboratory, a 70-person group that is the largest contractor of preclinical toxicology studies to the National Institutes of Health.
Mirsalis has a broad background in drug development, and has personally been involved in the development of more than 50 therapeutics that have entered clinical trials. He has also published extensively in the areas of genetic toxicology, mechanisms of carcinogenesis, development of therapeutics for cancer and infectious disease, and use of transgenic animals; he is the author of more than 125 publications, book chapters, and abstracts.
Before joining SRI, Mirsalis was a postdoctoral fellow at the Chemical Industry Institute of Toxicology, where he developed the in vivo-in vitro hepatocyte DNA repair assay, which is now widely used as a screen to identify potential carcinogens by government and industry. Mirsalis has an Adjunct Faculty appointment with the University of California, Santa Cruz, where he lectures regularly on genetic toxicology and carcinogenesis. He is a Past President of the Genetic and Environmental Toxicology Association of Northern California and a past Treasurer of the Environmental Mutagen Society.
Mirsalis received his B.S. degree in zoology/molecular biology from Kent State University, his M.S. degree in genetics from North Carolina State University, and holds Ph.D. degrees in toxicology and genetics from North Carolina State University. He has been certified by the American Board of Toxicology since 1983.
He was named an SRI Fellow in 2014.